This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Thromboelastography As A Tool for Possible Clopidogrel Resistance in The Patients Treated With Primary PCI for STEMI

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified July 2007 by Assaf-Harofeh Medical Center.
Recruitment status was:  Not yet recruiting
Information provided by:
Assaf-Harofeh Medical Center Identifier:
First received: August 15, 2007
Last updated: August 16, 2007
Last verified: July 2007
Determine usefulness of thromboelastography (TEG) as a valuable tool in ex-vivo assessing platelet response to aspirin and clopidogrel (dual) treatment and on-treatment platelet reactivity during acute ST segment elevation myocardial infarction (STEMI) in an acute phase during primary PCI (PPCI) and also during recovery been on maintenance medical therapy and to determine the correlation between platelet response to clopidogrel treatment and the outcome of patients.

Condition Intervention
Myocardial Infarction Cardiovascular Disease Procedure: Blood Sample

Study Type: Observational
Study Design: Observational Model: Defined Population
Observational Model: Natural History
Time Perspective: Longitudinal
Time Perspective: Prospective

Resource links provided by NLM:

Further study details as provided by Assaf-Harofeh Medical Center:

Estimated Enrollment: 50
Study Start Date: August 2007
Estimated Study Completion Date: February 2008
Detailed Description:
Dual anti-aggregant therapy is recommended standard of therapy applicable to all patient groups undergoing PPCI. The aspirin-clopidogrel regiment is signed to every patient without assessing therapeutic effect. In face of growing evidence of platelet resistance to the standardized therapy there is a demand for reliable diagnostic tool for rapid and accurate assessment of platelet reactivity. TEG is an established technique to assess the quality of clot formation' used mainly in surgery and obstetrics to determine possible bleeding diathesis. Recently it became to be used in cardiology, where it can be a valuable tool to assess a response to antiplatelet therapy and its association with the outcome. However, there is a few data about use of TEG in STEMI patients undergoing PCI. Our study is designed to assess by TEG the platelet's response to clopidogrel treatment during acute STEMI in patients undergoing primary PCI and the correlation of this response with the long term outcome.

Ages Eligible for Study:   18 Years to 88 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • >18 years old STEMI patients admitted to ICCU and in whom the primary PCI is elected as treatment strategy would be enrolled

Exclusion Criteria:

  • Patient received thrombolytic therapy, chronic renal failure (GFR<40 ml/min), any known hematological dyscrasia
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00517478

Contact: Alex Blatt, MD 972-8-9779345
Contact: Ilia Litovchik, MD 972-8-9779347

Asaf Harofeh MC Not yet recruiting
Zerifin, Israel, 70300
Contact: Blatt Alex, MD    972-8-9779345   
Principal Investigator: Blatt Alex, MD         
Sponsors and Collaborators
Assaf-Harofeh Medical Center
Study Director: Alex Blatt, MD Cardiology Division, Assaf Harofeh Medical Center
Principal Investigator: Ilia Litovchik, MD Cardiology Division, Assaf Harofeh Medical Center
  More Information Identifier: NCT00517478     History of Changes
Other Study ID Numbers: 98/07
Study First Received: August 15, 2007
Last Updated: August 16, 2007

Additional relevant MeSH terms:
Cardiovascular Diseases
Myocardial Infarction
Pathologic Processes
Myocardial Ischemia
Heart Diseases
Vascular Diseases processed this record on September 21, 2017